Vironexis Biotherapeutics

ICYMI - We launched from stealth yesterday!! Vironexis was founded to translate the groundbreaking AAV-delivered T-cell immunotherapy technology invented by our co-founder Timothy Cripe, M.D., Ph.D., Chief of the Division of Pediatric Hematology/Oncology/Bone and Marrow Transplant at Nationwide Children's Hospital, into a new modality that could redefine the future of cancer treatment. Our TransJoin technology enables a patient’s body to express an engineered transgene that redirects T cells throughout the body to tumor cells. The proprietary technology requires only a single dose and provides a bridge that joins together T cells and tumor cells to promote long-term, continuous T cell-mediated tumor killing. Read Dr. Cripe’s published research on our foundational technology: https://lnkd.in/g2AtFK3f Learn more about our co-founders, our science, and our deep pipeline of 10+ product candidates: https://vironexis.com/ #genetherapy #AAV #immunotherapy #cancer #oncology #cancervaccine

Thanks, Elizabeth Eaton FirstWord Pharma for speaking with our co-founders Dr. Timothy Cripe, Samit Varma and Dr. Brian Kaspar about our platform technology, pipeline, and mission to help patients and transform cancer treatment with AAV-delivered T-Cell immunotherapy! Check out Elizabeth's in-depth article here: https://lnkd.in/eSZUsppa

We’re thrilled to launch Vironexis Biotherapeutics today, unveiling our TransJoin AAV Gene Therapy Platform and a pipeline of 10+ product candidates for blood-based cancers, solid tumor metastasis prevention, and a cancer vaccine! We've received FDA clearance of our IND application for VNX-101, our first product candidate, for the treatment of CD19+ acute lymphoblastic leukemia. We plan to enter the clinic with VNX-101 in Q4 2024, marking the first-ever clinical trial of an AAV-delivered cancer immunotherapy. Our foundational technology is based on pioneering research led by Dr. Timothy Cripe at Nationwide Children's Hospital. Dr. Cripe, along with seasoned gene therapy entrepreneur Samit Varma and notable gene therapy pioneer Dr. Brian Kaspar, are our co-founders. We're grateful to Drive Capital and Future Ventures, who led our $26M seed financing, and Capital Factory and Moonshots Capital, who also participated in the round. Read our launch press release: https://bit.ly/3MDXzB4 We’re excited to keep you updated on our progress as we work to revolutionize immunotherapy and transform the future of cancer treatment! #genetherapy #AAV #immunotherapy #cancer #oncology #cancervaccine